天津发展子公司力生制药已完成721万股回购,股票激励计划已获正式采纳

财中社
06 Feb

  天津发展(00882)发布公告,公司间接非全资附属公司天津力生制药股份有限公司采纳股份回购方案后,通过深圳证券交易所以集中竞价交易方式,自2024年12月25日至2025年1月9日,回购共计721万股普通股股份,价格区间为17.28元/股至18.50元/股,占其已发行股本约2.80%,总金额为1.29亿元。至此,该股份回购方案已获全面实施。721万股回购股份将用作股票激励计划下授予激励对象的限制性股份。

  有关批准股票激励计划的决议案已于2025年2月5日获力生制药股东于股东大会上正式通过。因此,股票激励计划已获正式采纳。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10